The enzyme blend, which includes a lipase enzyme, can help improve digestion for pancreatic insufficiency sufferers, including cystic fibrosis patients.
A microbial enzyme blend from Bio-Cat Inc. (Troy, VA) said to aid digestion in patients suffering from pancreatic insufficiency has been granted a U.S. patent (#8,071,089).
As the company describes, the enzyme blend, which includes a lipase enzyme, can help improve digestion for pancreatic insufficiency sufferers, including cystic fibrosis patients. According to company CEO Ed Schuler, “Digestion of foods in normal diets is a challenge for these types of patients due to many complicating factors associated with the disease. Our innovation is focused on providing a blend of enzymes that would help break down or digest materials normally found in everyday foods-namely, carbohydrates, lipids, and protein.”
Also, Schuler points out, because Bio-Cat’s enzyme blend is microbial based, patients now have an alternative to the animal-derived enzymes typically prescribed to address digestion issues. The company says it will conduct further clinical studies on the ingredient.
The patent is titled “Composition with fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrosis as well as people suffering from pancreatic lipase insufficiency.”
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.
New review paper highlights gut-brain benefits of novel herbal blend, Digexin
September 16th 2024NXT USA has announced the publication of a narrative review that offers an in-depth analysis of the efficacy and safety of its Digexin ingredient, which is a novel blend of Ashwagandha and okra extracts.